Hansoh Pharmaceutical has released new clinical data for its investigational insomnia drug HS-10506, showing no adverse effects on alertness, cognitive function, depression, or anxiety symptoms following treatment. The company also reported that no rebound insomnia occurred after discontinuation of the drug, according to a press release cited by the China Association for Promotion of International Pharmaceutical Innovation.
The findings build on earlier results presented at the 37th European College of Neuropsychopharmacology (ECNP) Congress held in Milan, Italy, from September 21 to 24, 2024. At that event, Hansoh Pharmaceutical shared data from a Phase 1b/2 clinical trial evaluating HS-10506, a novel high-affinity selective orexin-2 receptor (OX2R) antagonist, in healthy Chinese volunteers. The study was designed to assess the drug’s safety, tolerability, and pharmacokinetic profile after a single oral dose.
According to verified reports from the ECNP 2024 conference, the trial included 52 healthy participants divided into five dosage groups receiving 2.5mg, 7.5mg, 20mg, 40mg, or 60mg of HS-10506 or placebo. The research demonstrated that HS-10506 exhibited quality safety and tolerability up to the highest tested dose of 60mg, with favorable pharmacokinetic properties and the expected pharmacodynamic effect of somnolence. No deaths, serious adverse events, or treatment discontinuations due to safety concerns were reported during the study.
Common adverse events observed in the HS-10506 group included drowsiness, reported in 76.9% of participants receiving the active drug compared to 38.5% in the placebo group. Other frequently reported events were headache and dizziness, though specific rates for these were not detailed in the available sources. Importantly, the data indicated no significant impact on next-day alertness or cognitive performance, and no signs of depression or anxiety were emerging during or after treatment.
The absence of rebound insomnia following discontinuation is a notable finding, as this phenomenon — where sleep difficulties worsen after stopping sleep medication — is a concern with some existing hypnotics. Orexin receptor antagonists like HS-10506 represent a newer class of sleep aids that work by blocking the wake-promoting signals of orexin neuropeptides, potentially offering a different side effect profile than traditional GABA-targeting medications.
HS-10506 is classified as a Class 1 novel drug in China, indicating it possesses a unique chemical structure and mechanism of action not previously approved in the country. The drug is being developed specifically for the treatment of insomnia disorder, a condition affecting millions globally and characterized by persistent difficulty falling or staying asleep, or non-restorative sleep, despite adequate opportunity for rest.
Insomnia is not merely a nighttime issue; it is associated with daytime impairments such as fatigue, mood disturbances, reduced concentration, and increased risk of accidents. Chronic insomnia also correlates with long-term health risks including cardiovascular disease, diabetes, and depression. Treatments that improve sleep without compromising daytime functioning or carrying risks of dependence or withdrawal symptoms are highly sought after in clinical practice.
The ECNP Congress, where the initial HS-10506 data were presented, is one of Europe’s largest gatherings in translational neuroscience and neuropsychopharmacology, annually drawing approximately 6,000 researchers, clinicians, and scientists from around the world. The forum serves as a key platform for sharing advancements in brain health and mental disorders, making it a significant venue for early-stage psychiatric and neurological drug data.
Moving forward, Hansoh Pharmaceutical states that the accumulated safety and efficacy data support further clinical development of HS-10506 for insomnia. The next steps would typically involve larger Phase 2 or Phase 3 trials to confirm effectiveness in patient populations with diagnosed insomnia disorder, optimize dosing regimens, and continue long-term safety monitoring.
For stakeholders in the pharmaceutical and healthcare sectors, the progression of HS-10506 reflects ongoing innovation in sleep medicine, particularly in targeting the orexin system — a pathway increasingly recognized for its role in regulating sleep-wake cycles. Drugs in this class, such as suvorexant (Belsomra®) and lemborexant (Dayvigo®), are already approved in several markets, demonstrating the clinical viability of orexin antagonism for insomnia treatment.
As development continues, investors, healthcare providers, and patients will be watching for updates on HS-10506’s advancement through clinical trials. Official sources such as company press releases, regulatory filings with China’s National Medical Products Administration (NMPA), and peer-reviewed publications will be the primary channels for verified information.
Those interested in following the drug’s progress can refer to Hansoh Pharmaceutical’s official website and announcements from reputable medical conferences like ECNP or the American Academy of Sleep Medicine (AASM) for timely and credible updates.
We encourage readers to share their thoughts on emerging insomnia treatments and the role of innovation in global healthcare. Join the conversation by commenting below or sharing this article with others interested in medical science and pharmaceutical development.